Literature DB >> 12775575

von Willebrand factor but not alpha-thrombin binding to platelet glycoprotein Ibalpha is influenced by the HPA-2 polymorphism.

Hans Ulrichts1, Karen Vanhoorelbeke, Sandra Cauwenberghs, Stephan Vauterin, Hartmut Kroll, Sentot Santoso, Hans Deckmyn.   

Abstract

OBJECTIVE: Glycoprotein (GP) Ibalpha is the functionally dominant subunit of the platelet GPIb-IX-V receptor complex. The N-terminal domain of the GPIbalpha chain contains binding sites for alpha-thrombin and von Willebrand factor (VWF). The human platelet alloantigen (HPA)-2 polymorphism of the GPIbalpha gene is associated with a C/T transition at nucleotide 1018, resulting in a Thr/Met dimorphism at residue 145 of GPIbalpha. To study the structural and functional effects of this dimorphism, N-terminal fragments (AA1-289) of the HPA-2a and HPA-2b alloform of GPIbalpha expressed in CHO cells were used. METHODS AND
RESULTS: Of 74 moAbs directed against human GPIbalpha, 2 antibodies with epitope between AA1-59 could differentiate between both alloforms. In addition, VWF bound with a higher affinity to the recombinant HPA-2a fragment or to homozygous HPA-2a platelets. In contrast, no difference was found in the binding of alpha-thrombin to the recombinant alloform fragments or of antibodies directed against the alpha-thrombin binding anionic sulfated tyrosine sequence (AA269-282).
CONCLUSIONS: Whereas the Thr145Met dimorphism does not affect alpha-thrombin binding, it does influence the conformation of the N-terminal flanking region and first leucine-rich repeat of GPIbalpha and by this has an effect on VWF binding.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12775575     DOI: 10.1161/01.ATV.0000079510.23517.43

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  6 in total

1.  Key role of glycoprotein Ib/V/IX and von Willebrand factor in platelet activation-dependent fibrin formation at low shear flow.

Authors:  Judith M E M Cosemans; Saskia E M Schols; Lucia Stefanini; Susanne de Witt; Marion A H Feijge; Karly Hamulyák; Hans Deckmyn; Wolfgang Bergmeier; Johan W M Heemskerk
Journal:  Blood       Date:  2010-10-29       Impact factor: 22.113

2.  Human platelet alloantigens HPA-1, HPA-2, and HPA-3 polymorphisms associated with extent of severe coronary artery disease.

Authors:  Nesrine Abboud; Lakdhar Ghazouani; Sonia Ben-Hadj-Khalifa; Fatma Anabi; Faouzi Added; Ali Khalfallah; Brahim Nsiri; Wassim Y Almawi; Touhami Mahjoub
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

Review 3.  Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development.

Authors:  Marlene S Williams; Ethan J Weiss; Marc S Sabatine; Daniel I Simon; Wadie F Bahou; Lewis C Becker; Leslie V Parise; Harold L Dauerman; Patricia A French; Susan S Smyth; Richard C Becker
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-12       Impact factor: 8.311

4.  Platelet GPIbalpha, GPIV and vWF polymorphisms and fatal pre-hospital MI among middle-aged men.

Authors:  Minna Pellikka; Lassi Narhi; Markus Perola; Antti Penttila; Pekka J Karhunen; Jussi Mikkelsson
Journal:  J Thromb Thrombolysis       Date:  2007-07-11       Impact factor: 2.300

5.  Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor.

Authors:  Simon F De Meyer; Karen Vanhoorelbeke; Marinee K Chuah; Inge Pareyn; Veerle Gillijns; Robert P Hebbel; Désiré Collen; Hans Deckmyn; Thierry VandenDriessche
Journal:  Blood       Date:  2006-02-14       Impact factor: 22.113

6.  Molecular typing of human platelet antigens in immune thrombocytopenia patients in northern Brazil.

Authors:  Julia Cavalcante do Carmo; Prissyla de Souza Klippel; Sabrine da Costa Cordeiro; Ângela Maria Dos Santos Fernandes; Raquel Medeiros Pinto; Simone Schneider Weber; Cleiton Fantin
Journal:  Rev Bras Hematol Hemoter       Date:  2017-02-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.